Search

Boehringer Ingelheim Vetmedica, Inc. to Establish North America and U.S. Headquarters in Duluth, Ga. Following Close of BI/Sanofi Asset Swap

Being a better ally at work

We’re always identifying ways to be better allies to one another at our family-owned company.

Yankees Baseball Legend Bernie Williams Raises Awareness of Devastating Lung Disease – IPF – in Honor of his Dad

Yankees Baseball Legend Bernie Williams Raises Awareness Of Devastating Lung Disease – Ipf – In Honor Of His Dad

Boehringer Ingelheim and Eli Lilly and Company announce positive top-line pivotal Phase III data results for empagliflozin

Boehringer Ingelheim and Lilly provide update on Jardiance® phase III exercise ability studies in chronic heart failure

Vetmedica Inc to Sell Vaccine Portfolio | Boehringer Ingelheim US

Read more on Boehringer Ingelheim Vetmedica Inc. entering into an agreement to sell feline, canine and rabies vaccines to Elanco Animal Health in the USA.

FDA Approves Boehringer Ingelheim’s STIOLTO™ RESPIMAT® Inhalation Spray as Once-Daily Maintenance Treatment for COPD

200 employees make a difference with record-breaking volunteer efforts

Discovery Research Global Post-Doc Program

FDA Approves Boehringer Ingelheim’s Striverdi® Respimat® (olodaterol) Inhalation Spray for Maintenance Treatment of COPD

Efficacy and safety of Ofev® (nintedanib) reinforced in new presentations at ATS 2018

Sanofi and Boehringer Ingelheim confirm Closing of business swap on January 1st 2017

Jardiance® (empagliflozin) Lessened Risk of Heart Failure | Boehringer Ingelheim US

The EMPRISE real-world study shows JARDIANCE saw a decreased risk of hospitalization for heart failure. View ISI, PI and Med Guide.

Galym Zhunisbekov

Galym Zhunisbekov, a Regional Regulatory Affairs Manager in Eastern Europe, talks about our philosophy and impact on patients’ lives.

When Passion Starts as a Family Value and Continues as a Work Value

Discover who inspires members of our LatinX Business Resource Group.

BI initiates Study of Sequencing in EGFR Lung Cancer | BI US

Boehringer Ingelheim has initiated a real-world study to assess the impact of sequential therapy in patients with EGFR mutation-positive advanced NSCLC.

Respiratory

Study analysis available during ATS 2021 supports long-term treatment with Ofev® in patients with systemic sclerosis-associated interstitial lung disease

Top-line Phase II Data for treatment of MASH

Boehringer Ingelheim and Zealand Pharma announced top-line Phase II data for treatment of metabolic dysfuntion-associated steatohepatitis (MASH).

More Green | Sustainable Development | Boehringer Ingelheim US

Our MORE GREEN pillar encompasses initiatives that consider many different aspects: adopting measures to avoid water and air pollution, & much more.

Onboarding

Boehringer Ingelheim and Lilly Announce Clinical Trial Collaboration in Metastatic Breast Cancer

Helping a Local Community in a Time of Need

History of our Logo | Corporate Profile | Boehringer Ingelheim US

The logo used by Boehringer Ingelheim today is a stylized depiction of the central section of the imperial palace of Charlemagne.

Celebrating Innovation | Partnering

BI’s Innovation Prize was established in Boston in 2015 to recognize the challenge and dedication of entrepreneurs in advancing new ideas & science.

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers